UNSPSC 51313439: Thenyldiamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H19N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZQC1892H9, chemically known as 1,2-ethanediamine, n,n-dimethyl-n-2-pyridinyl-n-(3-thienylmethyl)-, monohydrochloride but more generally known as thenyldiamine hydrochloride, which bears US NIH Compound Identifier 13734. European Medicines Agency schedules Thenyldiamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15510MIG.

UNSPSC 51313439 Thenyldiamine hydrochloride is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which involves thenyldiamine hydrochloride specifically. The mismatch suggests either misclassification in the posting systems or that the code is used as a catch-all placeholder for pharmaceutical product procurements that do not fit narrower commodity classifications. State and local buyers are soliciting the code through a county health department, a state health and human services commission, and a multistate cooperative purchasing alliance, indicating broad use across jurisdictional tiers for pharmaceutical supply-chain management.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, and quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescriptions program serving state employee and retiree health plans outside traditional pharmacy benefit manager channels. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, with a March 26, 2026, response deadline to establish contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The MMCAP solicitation carries a two-year contract term and reserves the right to make sole, dual, or multi-awards based on therapeutic and safety considerations.